Trials / Completed
CompletedNCT00160186
Gastrectomy Study: Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy
Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate BMI and the nutritional parameters of Creon (pancreatin) versus placebo after a total or subtotal gastrectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pancreatin | 2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks) |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2006-05-01
- Completion
- 2006-05-01
- First posted
- 2005-09-12
- Last updated
- 2008-03-31
Locations
9 sites across 4 countries: Denmark, Finland, Norway, Sweden
Source: ClinicalTrials.gov record NCT00160186. Inclusion in this directory is not an endorsement.